Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
Topical finasteride is considered a safer option for hair regrowth with fewer systemic side effects compared to oral finasteride. Some users report similar efficacy and side effects between topical and oral treatments, while others prefer topical due to reduced systemic exposure.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
A 20-year-old male's significant hair growth after two months of using 0.25mg Finasteride. The discussion includes varying opinions on the effectiveness and side effects of the treatment, with some users planning to try or adjust their Finasteride dosage.
User LateNightCoffeeShop shared progress after 3 months using Finasteride, Minoxidil, and Derma-rolling for hair regrowth. Users discussed treatment frequency, effectiveness, and potential side effects.
A method for treating androgenic alopecia using minoxidil, antiandrogens, exercise, and cold exposure to promote hair growth. Environmental factors and lifestyle changes, like diet and exercise, can improve treatment effectiveness.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Treating androgenic alopecia with minoxidil, finasteride, and antiandrogens, alongside exercise, cryotherapy, and natural substances to stimulate cold receptors for better hair growth. The method focuses on enhancing treatment effectiveness by considering environmental and behavioral factors and the role of cold receptors and muscle stress.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
Potential side effects of 5AR inhibitors like finasteride and dutasteride. Users debate risks, benefits, and personal experiences with these hair loss treatments.
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
Finasteride significantly increased testosterone levels for the user, with no major side effects except watery semen, which was resolved with zinc supplements. The user's hairline stopped receding and slightly improved.
A user shared their 3-month hair regrowth progress using 1mg finasteride, 5% minoxidil, and ketoconazole shampoo. Commenters noticed improvement and discussed the importance of waiting 6 months for more significant results.
User sees subtle regrowth after two months using topical dutasteride, oral minoxidil, dermastamp, and oral castor oil. Others suggest waiting a few more months to properly evaluate results.
People discussing hair loss treatments emphasize the need for patience, as results from using finasteride and minoxidil can take 8-12 months or longer. Some users report early signs of improvement, while others experience continued shedding or slower progress.
The user has been using 5% Minoxidil foam twice daily, microneedling every two weeks, and Nizoral 2% shampoo weekly for hair loss treatment. They've seen improvements in their hairline and eyelashes, and are considering adding finasteride to their regimen.
The user has been using finasteride, dutasteride, and RU58841 for hair loss without success and feels extremely uncomfortable with their appearance, including being bald and short. They express deep unhappiness and social isolation. Suggestions from others include adopting stoicism, focusing on personal development, considering a hair system, improving fashion, working out, and seeking therapy for mental health.
A user who has had positive results from using a regimen of microneedling, finasteride, minoxidil, peppermint oil, keto shampoo and DHT organic shampoo for hair growth. The conversation also addressed whether to use .5mg or 1mg of finasteride and the difference between dermapens and rollers.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
The post and conversation are about a user's progress in treating hair loss using oral finasteride and topical minoxidil. The user expresses regret for not starting treatment earlier.
HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
A user who shared progress pictures of their scalp using a microscope camera, demonstrating the difference between healthy and miniaturized hair. Various explanations for the cause of this were discussed, such as DHT build-up in scalp sebum causing an autoimmune response leading to inflammation and eventual hair loss, with some suggesting a do-it-yourself treatment involving adding ascorbic acid powder to shampoo.
The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.